On November 24, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) reported that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 11:20 a.m. Eastern Time (Press release, Gilead Sciences, NOV 24, 2020, http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-present-3rd-annual-evercore-isi-healthconx [SID1234571669]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast can be accessed at the company’s investors page at investors.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.

On November 24, 2020 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, NOV 24, 2020, View Source [SID1234571667]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler’s 32nd Annual Healthcare Conference on Tuesday, December 1, 2020. The pre-recorded presentation is currently available on the company’s website.

Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:00 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On November 24, 2020 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that it will be hosting a virtual investor event to provide a review of the Company’s oral, potent and selective menin inhibitor, KO-539, following the oral presentation of preliminary clinical data at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Kura Oncology, NOV 24, 2020, View Source [SID1234571664]). The event will feature members of the Kura management team along with two of the investigators from KOMET-001, an ongoing Phase 1/2A clinical trial of KO-539. The virtual event will take place at 2:00 p.m. ET / 11:00 a.m. PT on Saturday, December 5, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live video webcast of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the conclusion of the event.

On November 24, 2020 Kaleido Biosciences, Inc. (Nasdaq: KLDO), reported that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020 (Press release, Kaleido Biosciences, NOV 24, 2020, View Source [SID1234571663]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for registered attendees via the Piper Sandler conference site during the conference until December 3, 2020, and will also be available November 30, 2020, on the Investors & Media section of the Kaleido website at View Source An archived replay will be accessible for 90 days following the event.

On November 24, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020 (Press release, Genprex, NOV 24, 2020, View Source [SID1234571662]). Genprex’s Executive Vice President and Chief Operating Officer, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Diamond Equity Research Emerging Growth Invitational

Date: Tuesday, December 1

Time: 11:40 a.m. EST

Registration Link: https://bit.ly/2UJS3Si

A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.